Portage Biotech reports $6.8 million net loss in fiscal year 2025, a significant decrease from $75.4 million in fiscal year 2024. Expenses decreased in R&D and G&A categories. Company had $1.7 million in cash with $1.1 million in total current liabilities as of March 31, 2025.
Portage Biotech Inc. reported its financial results for the fiscal year ended March 31, 2025. They incurred a net loss of approximately $6.8 million, down significantly from the previous year's loss of $75.4 million. Operating expenses decreased to $7.4 million in 2025 from $18.2 million in 2024, with R&D expenses dropping by approximately $9.4 million primarily due to lower clinical trial costs. G&A expenses also decreased by $1.4 million. The Company had cash and cash equivalents of approximately $1.7 million and total current liabilities of about $1.1 million as of March 31, 2025. The Company is focused on advancing a pipeline of novel biologics for immuno-oncology. Risk factors and forward-looking statements are included in their disclosure.